Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer.
Ma X, Rousseau V, Sun H, Lantuejoul S, Filipits M, Pirker R, Popper H, Mendiboure J, Vataire AL, Le Chevalier T, Soria JC, Brambilla E, Dunant A, Hainaut P; IALT-Bio working group.
Ma X, et al. Among authors: pirker r.
Mol Oncol. 2014 May;8(3):555-64. doi: 10.1016/j.molonc.2013.12.015. Epub 2014 Jan 15.
Mol Oncol. 2014.
PMID: 24495481
Free PMC article.
Clinical Trial.